Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration

Area of Science:

• Cardiovascular Research
• Regenerative Medicine
• Stem Cell Biology

Background:

• The heart was long considered unable to regenerate after injury.
• Recent research challenges this dogma, focusing on stem cell potential.
• Congestive heart failure treatment is an active area of research.

Purpose of the Study:

• To investigate the potential of CD117+ stem cells for myocardial regeneration.
• To determine the therapeutic window for stem cell infusion post-myocardial infarction.
• To evaluate the impact of stem cell therapy on cardiac function and tissue repair.

Main Methods:

• Animal studies involving direct injection or mobilization of bone marrow-derived CD117+ (c-kit+) stem cells.
• Intravenous infusion of stem cells at various time points after myocardial infarction.
• Assessment of cardiac myocyte regeneration, left ventricular function, and infarct size.

Main Results:

• Increased CD117+ stem cells in cardiac tissue promote myocardial regeneration and improve cardiac function.
• Stem cell administration at the time of or prior to myocardial infarction leads to cardiac myocyte regeneration.
• Intravenous stem cell infusion up to 2 days post-myocardial infarction decreased infarct size, increased vascular density, and improved left ventricular function.

Conclusions:

• Bone marrow-derived CD117+ stem cells can regenerate cardiac tissue and improve function after myocardial infarction.
• The therapeutic window for stem cell treatment extends up to 2 days post-infarction.
• Stem cell therapy represents a promising alternative treatment for congestive heart failure.